Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-022-12725-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmaceuticals in the environment: A strategy for prioritizing molecules of environmental concern.
Chemosphere
November 2024
Laboratory of Integrated Sciences, Universidade Federal de São Paulo, Diadema, SP, CEP 09972-270, Brazil; Department of Environmental Sciences, Laboratory of Ecology and Nature Conservancy (LECON), Group of Landscape Ecology and Conservation Planning (LEPLAN), Universidade Federal de São Paulo, Diadema, CEP 09972-270, Brazil; Antimicrobial Resistance Institute of São Paulo (ARIES), São Paulo, Brazil. Electronic address:
Article Synopsis
- * The proposed strategy focuses on antineoplastics with low biodegradability and significant ecological risks, utilizing data from São Paulo, Brazil, to predict the mass of these drugs entering waterways and creating a prioritization index based on multiple risk factors.
- * Key prioritized antineoplastics identified include Paclitaxel and Cisplatin, highlighting the strategy's versatility for adapting to different contexts and improving drug environmental impact assessments.
Texture analysis can predict response to etoposide-doxorubicin-cisplatin in patients with adrenocortical carcinoma.
J Endocrinol Invest
October 2024
Department of Medicine-DIMED, University of Padova, Padova, Italy.
Article Synopsis
- Adrenocortical carcinoma (ACC) is a rare and aggressive cancer treatment often involving a chemotherapy regimen called EDP-M (etoposide, doxorubicin, cisplatin, and mitotane) for advanced stages.
- A study analyzed the relationship between CT textural features at diagnosis and treatment response, enrolling 17 patients and using various evaluation criteria.
- Results indicated that specific textural features, such as long-run high grey level emphasis and histogram kurtosis, could predict treatment response, showing a promising accuracy in differentiating between responders and non-responders.
Ruptured triple hormone-secreting adrenal cortical carcinoma with hyperaldosteronism, hypercortisolism, and elevated normetanephrine: a case report.
J Yeungnam Med Sci
October 2024
Division of Endocrinology, Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea.
We report a case of a ruptured triple hormone-secreting adrenal mass with hyperaldosteronism, hypercortisolism, and elevated normetanephrine levels, diagnosed as adrenal cortical carcinoma (ACC) by histology. A 53-year-old male patient who initially presented with abdominal pain was referred to our hospital for angiocoagulation of an adrenal mass rupture. Abdominal computed tomography revealed a heterogeneous 19×11×15 cm right adrenal mass with invasion into the right lobe of the liver, inferior vena cava, retrocaval lymph nodes, and aortocaval lymph nodes.
View Article and Find Full Text PDFEtoposide, cisplatin, and sintilimab combined with anlotinib in successful treatment of adrenocortical carcinoma with lung metastasis: a case report.
Front Oncol
August 2024
School of Clinical Medicine, Binzhou Medical University, Binzhou, China.
Background: Adrenocortical carcinoma (ACC) is a rare malignant tumor that occurs in the adrenal cortex. It has a high degree of malignancy and comparatively poor overall prognosis. Surgery is the standard curative therapy for localized ACC patients.
View Article and Find Full Text PDFActivity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
Cancer Res Commun
March 2024
Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Article Synopsis
- Current treatments for metastatic adrenocortical carcinoma (ACC), like mitotane and cytotoxic agents, are not very effective, leading researchers to explore new options.* -
- The study identified TAK-243, a novel inhibitor that works by disrupting protein ubiquitination, and it shows strong potential for killing ACC cells both alone and in combination with existing therapies.* -
- TAK-243 demonstrated promising results in preclinical models, including patient-derived organoids and mouse studies, warranting further investigation in clinical trials for advanced-stage ACC patients.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!